

**7th KOLKATA LIVER MEETING**  
**6th, 7th and 8th Dec, 2018**  
**Theme: Non-alcoholic Fatty Liver Disease**

**Thursday, 6th December , 2018**

TIME	SESSIONS	DURATION (Mins)	SPEAKER
12:30 - 14:00	<b>LUNCH</b>		
14:00 - 16 :15	<b>Session 1 :: NASH - The Disease</b>		
	<b>Chairperson: Vivek Saraswat, Anoop Saraya, K Narayanasamy, Tarun Lahiri Majumdar, V M Dayal</b>		
14:00-14:20	NASH is a multisystemic disease	20	Arun Sanyal
14:20- 14 40	NASH is all about Fibrosis : Clinical and economic implications	20	Zobair Younossi
14:40-15:00	How do you identify the patient with "Progressive NASH"	20	Ajay Duseja
15:00- 15 :20	What is the Spectrum of Advanced NASH and HCC ?	20	Jacob George
15 :40- 16:00	Diabetes and NAFLD : Two sides of the Same coin	20	V Mohan
16:00 -16 15	Discussion	15	
16:15 to 16 40 pm	<b>COFFEE</b>		
16:40 to 18:10 5:00:00	<b>Session 2: NASH - Pathology</b>		
	<b>Chairperson: Y K Chawla, N Murugan, Ramesh Kumar</b>		
16:40 - 17:00	NASH - Histological characteristics and diagnosis	20	David Kleiner
17:00 - 17:20	Can we correlate Histology with clinical Outcomes ?	20	Rohit Loomba
17:20- 17:40	NAS scoring systems :: How they can guide therapy and in what time frame ??	20	David Kleiner
17:40 - 18:00	Are we any closer to digital pathology aided with machine learning ?	20	Arun Sanyal
18:00 - 18 :10	Discussion	10	
18:10- 19-10 pm	<b>Session 3: NASH - Extrahepatic diseases</b>		
	<b>Chairperson: S P Mishra, Showkat Zargar, N P Bohidar</b>		
	NASH in India : Diversity and Distinctiveness	20	Abhijit Chowdhury
	Fatty Liver Disease in ACLF Context	20	Rakhi Maiwal
	Cardiovascular Disease in NASH - Not just an Association	20	Jacob George
	Discussion	10	
20:35 onwards	<b>DINNER</b>		

**Friday 7th December , 2018**

**7th KOLKATA LIVER MEETING**  
**6th, 7th and 8th Dec, 2018**  
**Theme: Non-alcoholic Fatty Liver Disease**

TIME	SESSIONS	DURATION (Mins)	SPEAKER
09:00 - 10:50 am	<b>Session 4 : NASH Evaluation - Clinical</b>		
	<b>Chairperson: P N Rao, Harikumar Nair, G N Yattoo, Sethu Babu, N S Behl</b>		
	NASH Evaluation - An Overview	20	Laurent Castera
	MR Elastography and Mangement of NASH - Application	20	Richard Ehman
	MR PDFF in prediction of disease outcome and monitoring of therapy	20	Rohit Loomba
	Vibration controlled Transient Elastography in NASH mangement	20	Laurent Castera
	Availble Serum Bio MARKERS in NASH : Are they Useful in clinical settings	20	Ashwani Singhal
10:50 - 11:00	Coffee break		
11:00 - 12:50	<b>Session 5: NASH Pathophysiology</b>		
	<b>Chairperson: A C Anand, B D Goswami, K T Shenoy, V M Dayal , Partha Chakravarty</b>		
	Is Insulin Resistance Central in NASH pathogenesis ?	20	Gerald Shulman
	Mitochondrial dysfunctions and altered Metabolic Flux in NASH	20	Kitt Petersen
	Lipototoxicity is a major Driver of NASH pathogenesis	20	Harmeet Malhi
	Inflammation in NASH : Cells , pathways , networks and Disease	20	Fabio Mara
	Putting the pieces in NASH pathogenesis together	20	Arun sanyal
	Discussion	10	
12:50 - 13:30	<b>A. K. Basu Memorial Oration</b>		
12:50 - 13:31	<b>Chairperson: Ashokananda Konar, Kalyan Bose</b>		
	<b>"NASH as a reflection of modern mankind</b>	40	Arun Sanyal
13:30 - 14:30	<b>LUNCH</b>		
14:30 - 15:50	<b>Session 6 : NASH - Clinical Decision making and Overlaps</b>		
	<b>Chairperson: Sunil Dadhich, Abraham Koshy, B C Sharma</b>		
	A case of NASH and management issues - multi organ and Multiple etiologies	30	Shalimar
	NASH and ASH - The Two wings of a Fire so common	20	Ashwani Singhal
	NASH and Viral Hepatitis - natural History and therapy issues	20	Kaushal Madan
	Discussion	10	

**7th KOLKATA LIVER MEETING**  
**6th, 7th and 8th Dec, 2018**  
**Theme: Non-alcoholic Fatty Liver Disease**

15:50 - 17:00	<b>Session 7 : NASH - Disease Modifiers and Implications</b>		
	<b>Chairperson: P N Rao , Debashis Dutta, M A Mahtab</b>		
	Genetics and Epigenetics of NASH - Can they influence patient mangement ?	20	Julia Kozlitina
	Microbiome changes in NASH : cause or Effect	20	Lixin Jhu
	Integrating "Omics" Information TO Drug Development	20	Mani Subramanian
	Discussion	10	
17:00 - 17:20	COFFEE BREAK		
17:20 - 18:30	<b>Session 8 : NASH - Across the Globe and lessons</b>		
	<b>Chairperson: Krishnadas Devadas, Sujit Chowdhury, Rajesh Gopalakrishna</b>		
	Screening for NASH in the General Population and Speciality Linkage - Spanish	20	Jose Luis Calleja
	NASH in the Far East	20	Chan Wah Kheong
	Efforts to alter the NASH epidemic world wide - an integrated approach	20	Zobair Younossi
	Discussion	10	
19:30 ONWARDS	<b>DINNER</b>		
<b>Saturday 8th December , 2018</b>			
<b>TIME</b>	<b>SESSIONS</b>	<b>DURATION (Mins)</b>	<b>SPEAKER</b>
<b>Saturday 8th December , 2018</b>			
<b>TIME</b>	<b>SESSIONS</b>	<b>DURATION (Mins)</b>	<b>SPEAKER</b>
08.00-09.00	Hepatology Quiz		Quizmaster: Saptarshi Bishnu, Dipankar Mondal
09:00 - 11:00	<b>Session 9 :: Navigating the Maze of Molecules in Clinical Trials</b>		
	<b>Chairperson: P N Rao, Premashis Kar, Mamun-al-Mahtab, Kingsuk Das, B R Medhi</b>		
	Overview of the landscape: Compounds and End points	20	Rohit Loomba
	Targeting nuclear hormone modulators and metabolic enzymes	20	Bart Staels
	Saroglitazar - The Global "Indian" NASH molecule	10	Deven Parmar

**7th KOLKATA LIVER MEETING**  
**6th, 7th and 8th Dec, 2018**  
**Theme: Non-alcoholic Fatty Liver Disease**

	Modulating inflammation and fibrosis	20	Fabio Mara
	Ammonia Modulations :: Role in NASH THERAPY	20	Rajiv Jalan
	Monotherapy or combination therapy for NASH?	20	Arun Sanyal
	Discussion	10	
<b>11:00 - 12:30</b>	<b>Session 10 :: Complimentary approaches and addressing root cause of NASH</b>		
	<b>Chairperson: Ananta Sreshtha, Nagarjuna Kumar, Rajasekhar Perumalla, Manisha Dwivedi</b>		
	Reversing insulin resistance: antidiabetics and/or uncoupling?	25	Gerald Shulman
	Bariatric Surgery in NASH : An Overview of Types of surgery and Mechanisms of improvement	20	Jacob George
	Life Style Modifications in the era of pharmacotherapy	15	Akash Shukla
	How long will we have to treat NASH once effective pharmacotherapy is available - an outcome perspective	20	Zobair Younossi
	Discussion	10	
<b>12:30 - 12:45</b>	<b>COFFEE</b>		
<b>12:45- 13:45</b>	<b>Session 11: Future Perspective</b>		
	<b>Chairperson: Vivek Saraswat ,G K Dhali,Gaurav Pandey</b>		
	Basic research in in NASH and its' impact - the years Ahead	20	Scott Friedman
	Global initiatives on developing biomarkers	20	Arun Sanyal
	How I evaluate and treat a patient with NASH today and How I will in 2020	20	Rohit Loomba
<b>14:00 onwards</b>	<b>Lunch and Closure</b>		